A novel role for apatinib in enhancing radiosensitivity in non-small cell lung cancer cells by suppressing the AKT and ERK pathways

BACKGROUND: Radioresistance is still the major cause of radiotherapy failure and poor prognosis in patients with non-small cell lung cancer (NSCLC). Apatinib (AP) is a highly selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). Whether and how AP affects radiosensitivity in...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lin, Li, Yuexian, Zou, Huawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2021
Materias:
Biochemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557687/
https://www.ncbi.nlm.nih.gov/pubmed/34760374
http://dx.doi.org/10.7717/peerj.12356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557687/
https://www.ncbi.nlm.nih.gov/pubmed/34760374
http://dx.doi.org/10.7717/peerj.12356

Ejemplares similares